Radhika Ayurveda Research and Development

Radhika Ayurveda Research and Development is an Indian pharmaceutical company focused on the research, development, and commercialization of evidence-based Ayurvedic and herbal medicines. The company's flagship product is GanjhuVir, a patented, broad-spectrum antiviral phytomedicine derived from the single plant source Desmodium gangeticum (Shalparni). GanjhuVir has undergone clinical trials for the treatment of dengue fever associated with thrombocytopenia and COVID-19, demonstrating efficacy in reducing viral load and accelerating platelet count recovery. Radhika Ayurveda Research and Development is dedicated to bridging traditional Ayurvedic principles with modern scientific validation to address viral infections and other chronic conditions.